2
Registered trials
0
Recruiting
2
Unique sponsors
1
Unique IMPs
1
Commercial trials
Drug classes (ATC)
—
ATC code not specified
1
L
Oncology (ATC L)
1
Mechanism of action (INN-stem analysis)
Checkpoint inhibitor (PD-1)
1 substance
Phase II:
1
Phase I (Other):
1
Phase II
1 trial-
EndedFundación Oncosur AcademicPEMBROLIZUMAB
Phase I (Other)
1 trial-
EndedAmgen Inc. CommercialIMP not specified
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Amgen Inc. | Commercial | 1 | Phase I (Other) | 0 |
| Fundación Oncosur | Academic | 1 | Phase II | 0 |
New trials by year
2021
1
2023
1